Results: 26

Distribución mutación BRAFsegún carac-terísticas epidemiológicas e histopatológicas en cáncer papilar de tiroides. Un estudio observacional de centro único
BRAFmutation distribution according to epidemiological and histopathological characteristics in papillary thyroid cancer patients. A single-center observational study

Oncología (Guayaquil); 33 (3), 2023
Introducción: El cáncer de tiroides se posiciona como una de las neoplasias más prevalentes en Ecuador, manifestándose típicamente en la cuarta década de vida, con una mayor inciden-cia en mujeres. El subtipo histológico predominante es el papilar (CPT), y diversos estudios han evidenciado que has...

Avaliação do status mutacional do éxon 15 do BRAF e sua relação com fatores prognósticos histopatológicos no melanoma acral de pacientes de instituição referência em oncologia
Evaluation of the mutational status of BRAF exon 15 and its relationship with histopathological prognostic factors in acral melanoma patients from a reference oncology institution

INTRODUÇÃO: Melanoma é a neoplasia cutânea mais letal. O melanoma acral é um subtipo de melanoma, definido como melanoma de palmas, de plantas e da região subungueal, sendo o tipo de melanoma cutâneo com pior prognóstico. Os melanomas devem ser testados para mutação no gene BRAF, devido à exis...

Enfermedad de Erdheim-Chester: primer caso pediátrico reportado en Colombia

Biomédica (Bogotá); 41 (4), 2021
Resumen | La enfermedad de Erdheim-Chester es una condición extremadamente rara en la edad pediátrica. Se presenta el caso de una niña de 12 años con diagnóstico histológico y radiológico de enfermedad de Erdheim-Chester multisistémica y mutación en el gen BRAF, que requirió tratamiento con dab...

Terapias dirigidas con inhibidores del braf en gliomas pediátricos de alto y bajo grado con la mutación brafv600e. Experiencia del hospital Prof. Dr. Juan P. Garrahan

Medicina (B.Aires); 81 (5), 2021
Resumen La mutación puntual V600E del gen BRAF juega un papel fundamental en la tumorigénesis de muchos gliomas. La inhibición de su producto forma parte de terapias innovadoras emergentes en los últimos años. Conocer el rol de estos tratamientos resulta imprescindible. El objetivo del trabajo fue d...

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic

SUMMARY Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary...

Papillary thyroid carcinoma with nodular fasciitis-like stroma: a rare variant

Autops. Case Rep; 11 (), 2021
Papillary thyroid carcinoma with desmoid-type fibromatosis (PTC-DTF) or nodular fasciitis-like stroma (PTC-NFS) is a rare morphological variant of PTC with a favorable prognosis. There is a paucity of molecular data regarding this entity. We present the case of a 20-year-old female who presented with a p...

Cytoplasmic-membrane egfr predicts expanded ras mutation status in colorectal carcinomas?

ABCD (São Paulo, Impr.); 34 (1), 2021
ABSTRACT Background: Inhibitors of the epidermal growth factor (EGFR) represent an effective therapeutic option for patients with metastatic colorectal carcinoma, free of activating mutations in KRAS and NRAS. However, the research of mutations is of high cost and scarcely accessible. The expression of ...

The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma

ABSTRACT Objective: Although the prognostic role of BRAFV600E mutation in papillary thyroid carcinoma (PTC) is controversial, the American Thyroid Association (ATA) includes the mutational status in their risk stratification system. To evaluate the impact of the BRAFV600E mutation status on PTC risk str...

Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case

Rev. méd. Chile; 148 (11), 2020
ABSTRACT MEK- and BRAF-inhibitors trametinib and dabrafenib are successfully used for BRAF-mutated, metastasizing melanoma, but these compounds may induce side effects. We report a 50 years old female with BRAF-mutated metastasizing melanoma who received trametinib (2 mg/d) and dabrafenib (200 mg/d) afte...